To include your compound in the COVID-19 Resource Center, submit it here.

Long-winded questions; short replies

Mark McClellan, the Bush administration's nominee to head the FDA, provided few real clues to what future agency policy might look like under his regime in written congressional testimony last week, although he did reveal some ambivalence about establishing a process for approving biologic generics and firm opposition to reimportation of pharmaceuticals from Canada.

McClellan provided terse responses to written questions posed by members of the Senate Health, Education, Labor and Pensions Committee. The answers - in most cases shorter than the lawmakers' queries - were

Read the full 854 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers